Merkel cell carcinoma (MCC) is a rare but aggressive neuroendocrine cutaneous malignancy, with a predilection for sun-exposed sites in elderly patients. Despite an incidence 30 times less than that of melanoma, its disease-specific mortality is three times higher. Management of MCC remains challenging because of a limited understanding of its molecular biology, lack of prospective clinical trials, and limitations associated with retrospective reviews of therapeutic options. With the recent discovery of an associated human polyomavirus, significant progress has been made in the understanding of the pathogenesis of this malignancy. With this progress, there has been increasing optimism regarding new tools in the therapeutic armamentarium to fight this deadly disease. Here we present an overview on MCC with an emphasis on the most recent biologic discoveries and the rationale for novel targeted and immunotherapies.
Orduz, Sara Yahel PatiñoJulio-César Cepeda-Ladino
Joaquín Fernando Bernal-RamírezJair N. Ojeda‐JoyaCamila Agudelo-RiveraFelipe Clavijo-RamírezCarolina Durana-ÁngelClark GrangerDaniel Esteban Osorio-RodríguezDaniel Parra‐AmadoJosé David PulidoJorge Enrique Ramos-ForeroDaniela Rodríguez-NovoaAndrés Mauricio Sánchez-JabbaJorge Hernán Toro-Córdoba